Viatris Launches Tender Offer to Acquire Pacira BioSciences for $36.50 a Share
Bitget2026/10/30 12:41- Viatris commenced a tender offer on Oct. 30, 2026, to acquire all outstanding Pacira BioSciences common shares for $36.50 each in cash.
- The offer expires one minute after 11:59 p.m. Eastern Time on Nov. 16, 2026, unless extended or terminated earlier.
- Completion requires more than 50% of outstanding shares, antitrust clearance and no legal restraints; the offer has no financing condition.
- Pacira will become a wholly owned subsidiary following completion of the offer and subsequent merger.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.

Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October


SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
